INTS vs MRVL · $7.7M cap vs P/E 100, rev $8.19B
Intensity Therapeutics, Inc. Common stock (INTS) versus Marvell Technology Group Ltd (MRVL) — a side-by-side from cached financials, not a winner call.
Intensity Therapeutics, Inc. Common stock (INTS) is a biotechnology company listed on US.
Marvell Technology Group Ltd (MRVL) is a semiconductors company listed on NASDAQ.
INTS does not have a complete income-statement cache yet.
Latest reported MRVL revenue for 2026-01-31 was $8.19B. Net income was $2.67B. Revenue was up 42.1% from 2025-02-01 to 2026-01-31. MRVL currently screens at market cap $253.51B and trailing P/E 99.8.
INTS currently screens at market cap $7.7M. MRVL currently screens at market cap $253.51B and trailing P/E 99.8.
Not investment advice. Open the INTS and MRVL stock pages for the full models.
Not investment advice.